XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological disorders. The company markets Gabapentin Enacarbil extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome and for the management of postherpetic neuralgia in adults under the Regnite name in Japan and five other Asian countries. The company’s lead product candidate is Arbaclofen Placarbil, a transported prodrug of R-baclofen that is in Phase III clinical trial for the potential treatment of spasticity in patients with multiple sclerosis (MS), stroke and cerebral palsy, and spinal cord injury. Its product candidates in clinical development also include XP21279, a transported prodrug of Levodopa, which has completed Phase II clinical trial for the treatment of Parkinson’s disease; and XP23829, a prodrug of monomethyl fumarate that is in Phase I clinical trial for the potential treatment of relapsing-remitting MS, psoriasis, and/or other disorders. The company has strategic alliance with Astellas Pharma Inc. to develop and commercialize Gabapentin Enacarbil under the Regnite name in Japan, Korea, the Philippines, Indonesia, Thailand, and Taiwan. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.

Key Statistics